National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 2, 2012, Pages 161-169

  Prah, Philip ^a   Petersen, Irene ^b   Nazareth, Irwin ^b   Walters, Kate ^b   Osborn, David ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic; Prescription; Primary care; Schizophrenia; Second generation (atypical); The Health Improvement Network

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE;

ADULT; AGE DISTRIBUTION; ARTICLE; DEMOGRAPHY; FEMALE; FOLLOW UP; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT DURATION; UNITED KINGDOM;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; SCHIZOPHRENIA; SEX FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84856279578     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2213     Document Type: Article

References (23)

1. Geddes J, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321(7273): 1371-1376.
2. Lieberman JA, et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N Engl J Med 2005; 353(12): 1209-1223.
3. Leucht S, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 1999; 35(1): 51-68.
4. Lehman AF, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161(suppl): 1-56.
5. NICE. Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal No. 43 2002 [accessed 16 June 2010]; Available from: .
6. NICE. The nice guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. National Clinical Guideline Number 82 2009 [accessed 16 June 2010]; Available from: .
7. Verdoux H, Tournier M, Begaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010; 121(1): 4-10.
8. Wheeler A, Humberstone V, Robinson G. Trends in antipsychotic prescribing in schizophrenia in Auckland. Australas Psychiatry 2006; 14(2): 169-174.
9. Ascher-Svanum H, et al. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006; 6: 8.
10. Akkaya C, et al. Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting. Human Psychopharmacology-Clinical and Experimental 2007; 22(8): p. 515-528.
11. Moisan J, Grégoire J-P. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis. Clin Ther 2010; 32(Supplement 1): S21-S31.
12. Ashcroft DM, et al. Variations in prescribing atypical antipsychotic drugs in primary care: cross-sectional study. Pharmacoepidemiol Drug Saf 2002; 11(4): 285-289.
13. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004; 12(3): 171-7.
14. Chisholm J. The Read clinical classification. BMJ 1990; 300(6732): 1092.
15. ONS. Census 2001 [accessed 23 September 2010]; Available from: .
16. Townsend P, Phillimore P, Beattie A. Health and deprivation: inequality and the North. Croom Helm: London, 1988.
17. Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf 2009; 18(1): 76-83.
18. Kaye JA, Bradbury BD, Jick H. Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. Br J Clin Pharmacol 2003; 56(5): 569-575.
19. Crump BJ, et al. Transferring the costs of expensive treatments from secondary to primary-care. Br Med J 1995; 310(6978): 509-512.
20. Roland M. Linking Physicians' Pay to the Quality of Care-A Major Experiment in the United Kingdom. N Engl J Med 2004; 351(14): 1448-1454.
21. Menzin J, et al. Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program. Psychiatr Serv 2003; 54(5): 719-723.
22. Dolder CR, et al. Antipsychotic Medication Adherence: Is There a Difference Between Typical and Atypical Agents? Am J Psychiatry 2002; 159(1): 103-108.
23. Smith M, et al. First- V. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008; 192(6): 406-411.